PM — Philip Morris International Inc.

Summary of PM Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Revenues: Over $10 billion, up 9% reported and 2.7% organically.
• Adjusted Operating Income: Grew 10% to $4.2 billion, with nearly 1% organic growth.
• Adjusted Diluted EPS: Increased 16% to $1.96, benefiting from an $0.18 currency tailwind.
• Adjusted Gross Profit: Rose 10% to $6.9 billion, with 3.8% organic growth and 70 basis points margin expansion.
• International Smoke-Free Business: Achieved double-digit volume growth and high teens organic gross profit growth.

2. Strategic Updates and Business Highlights

• Smoke-Free Products: Strong performance from IQOS, with 11% adjusted in-market sales growth. ZYN reached a joint #1 position in Europe.
• Combustibles: Low single-digit organic growth in net revenues and gross profit, attributed to effective pricing and cost management despite declining cigarette volumes.
• Investment in Growth: Continued investment in smoke-free portfolio, with expectations for U.S. performance to improve as comparisons normalize and new products are launched.
• Innovation: Focus on expanding product offerings, including ZYN Ultra and IQOS by bonds, to capture market share and enhance profitability.

3. Forward Guidance and Outlook

• Full-Year Expectations: Reaffirmed organic net revenue growth of 5% to 7%, operating income growth of 7% to 9%, and adjusted diluted EPS growth of 7.5% to 9.5%.
• Q2 Expectations: Anticipated strong international performance, with HTU shipment volumes of 40-42 billion and mid-single-digit organic net revenue growth.

4. Bad News, Challenges, or Points of Concern

• Cigarette Volume Declines: High-end declines were noted, with expectations of around 3% for the full year, influenced by economic conditions and regulatory changes.
• U.S. Market Dynamics: Competitive pressures in the nicotine pouch market, with ZYN experiencing shipment declines due to inventory normalization and increased promotional activities.
• Regulatory Environment: Ongoing uncertainties regarding FDA approvals for new products, which could impact growth trajectories.
• Economic Headwinds: Global economic uncertainty and rising costs from the Middle East conflict affecting supply chains and consumer behavior.

5. Notable Q&A Insights

• IQOS Profitability: Management emphasized the importance of maximizing volume alongside profitability, with ongoing pricing increases and supply chain efficiencies contributing to margin growth.
• ZYN Strategy: Confidence in ZYN's future performance was expressed, with expectations for improved dynamics in the second half of the year due to innovation and normalization of comparisons.
• Market Trends: Discussion on consumer dynamics in nicotine pouches, with potential for higher nicotine content products to drive growth.
• Regulatory Concerns: Management remains cautious about potential state-level excise taxes on nicotine pouches, advocating for differentiated taxation based on product risk profiles.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of PM's performance and outlook for Q1 2026.